Search Result for : Pharmaceutical

The Dollar Business Bureau A leading Indian pharmaceuticals company Aurobindo Pharma has said that it would widen its product portfolio in the American market while planning to enter new markets in the Europe, a part of the company’s growth strategy in the coming 3-4 years. In the US market, Aurobindo Pharma plans to widen its portfolio through faster growth in OTC, injectable and higher complexity products, the company said in a presentation to investors. However, in European market, the company plans to enhance its presence in new geographies like Czech Republic and Poland, in addition to strengthening its position in the existing markets of Germany, France, Spain, Netherlands and the UK. Aurobindo Pharma is the 6th largest generic company by volume in the US, ...

The Dollar Business Bureau  India and Jordan discussed ways of increasing bilateral trade and deepening their engagements for greater cooperation in investment sector at the 10TH India-Jordan Trade and Economic Joint Committee (TEJC) Meeting on Wednesday. During the TEJC meeting, the two sides also reaffirmed their mutual interest and discussed the roadmap for cooperation in various fields such as Fertilizer Sector, Customs, Double Taxation Avoidance Agreement, Visa and Consular issues, Health and Pharmaceuticals, Micro, Small and Medium Enterprises, Maritime Transport, Rail Transport, and Air Transport, Renewable Energy, Energy Efficiency, and Smart Grid development, Information Technology, Higher Education and Vocational Training, Agriculture sector etc. The government press release said, that the Indian side represented by the Commerce and Industries Minister, Nirmala Sitharaman and Yarub ...

By Ranjeet Mahtani & Sweta Rajan On the path to complete all responsibilities and release the requisite laws, regulations and rates ahead of the proposed transition date of July 1, 2017, the GST Council met on June 3, 2017. The key developments during the meeting were: A committee comprising revenue officers from Centre and States is to be set up to entertain complaints relating to anti-profiteering. GST rates of the items which were not placed across the agreed rate slabs (after the Council’s meetings on 18 and 19 May, 2017) were decided, including 3% GST on gold and gold jewellery, 0.25% on rough diamonds, 5% on packaged food items sold under registered trademarks, 18% on biscuits, 5% on footwear priced below Rs. 500/- ...

The Dollar Business Bureau In a much-needed relief to the exporters, the Export Credit Guarantee Corporation (ECGC) in its 60th year of operation has taken a customer friendly step by reducing the premium rate by an average of 17% for its whole turnover policy covers. This has reduced the transaction costs for short term business exporters from Rs.28.19 to Rs 25.46 per Rs 100 during FY 2016-17. The premier Export Credit Agency has also initiated several customer friendly steps to boost exports. In its press release on May 31st, the agency has listed out the initiatives taken during FY 2016-17. The agency has taken steps to make Export Factoring Scheme, cheaper for MSMEs. To give a fillip to the Medium & Long Term (MLT) ...

PTI Encouraged by Infosys' decision to set up a tech centre in his state and generate 2,000 jobs, Indiana Governor Eric Holcomb will lead a high- powered trade delegation to India later this year with the sole objective of attracting more Indian business, particularly IT companies. "I'm looking forward to travelling to India, probably in the fall, before the winter," Holcomb told PTI in an exclusive interview in his office at the State Capitol. Holcomb, who succeeded Vice President Mike Pence as Indiana governor, said he wanted to travel to India soon after his inauguration early this year but pressing engagements and now the summer prevented him from doing so. Holcomb, who would be the first Indiana governor ...

PTI  In a major relief to patients, the government has reduced prices of coronary stents by up to 400 per cent, capping them at Rs 7,260 for bare metal ones and Rs 29,600 for the drug-eluting variety. The National Pharmaceutical Pricing Authority (NPPA) in a notification said in public interest, it has fixed the ceiling price of bare metal stents at 7,260 and that of drug-eluting stents and bioresorbable vascular scaffold (BVS)/biodegradable stents at Rs 29,600. A coronary stent is a tube-shaped device placed in the arteries that supply blood to the heart. It keeps the arteries open in the treatment of coronary heart diseases. The maximum retail cost of a stent currently ranges from Rs 25,000 to Rs 1.98 lakh. ...

The Dollar Business Bureau  The Cabinet on Wednesday approved the sale of surplus land of the country’s first pharma company Bengal Chemicals and Pharmaceuticals Ltd. as well as Hindustan Antibiotics Ltd. The Cabinet headed by Prime Minister Narendra Modi also approved closure of Indian Drugs and Pharmaceuticals Ltd. (IDPL) and Rajasthan Drugs and Pharmaceuticals Ltd. (RDPL).  This is second such strategic sale approved in over 12 years. In September, the Prime Minister-chaired Cabinet had cleared the strategic sale of Bharat Pumps and Compressors Ltd. In 2003-04, the then Prime Minister Atal Bihari Vajpayee had approved the first strategic privatisation of Jessop and Co. Earlier, NITI Aayog had identified BCPL and HAL as the two public sector units for sale of government's majority stake to private companies ...

Sheela Mamidenna Laurus Labs, a Vijayawada based R&D focussed pharmaceutical firm will launch its Initial Public Offering (IPO) scheduled to open on December 6 and close on December 8, 2016. The company plans to raise through its IPO Rs.1331 crore from the primary market. The company was incorporated as a private limited company in 2005 and in that very year established its R&D centre at Hyderabad. Beginning in 2007, 2014 and 2015, the company set up 3 manufacturing units in Visakhapatnam, A.P. Laurus launched its first Commercialised four nutritional Fine Chemicals in Europe in 2009.  The company is now in a leadership position in generic active pharmaceuticals ingredients (APIs) for select high-growth therapeutic areas of anti-retrovirals (ARVs) and Hepatitis C. The company has made ...